度普利尤单抗在年轻移植患者特应性皮炎中的应用——3例病例系列报道
Use of dupilumab for atopic dermatitis in young transplant patients-A case series of 3 patients.
作者信息
Steele Maritza V, Gupta Rachit, Maguiness Sheilagh, Boull Christina
机构信息
School of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Department of Dermatology, University of Minnesota, Minneapolis, Minnesota, USA.
出版信息
Pediatr Dermatol. 2023 Sep-Oct;40(5):897-899. doi: 10.1111/pde.15280. Epub 2023 Feb 23.
Patients who undergo solid organ transplantation are at an increased risk of developing atopic dermatitis, potentially due to long-term use of calcineurin inhibitors which results in a shift towards the Th2 immune response. The effectiveness and safety of dupilumab for atopic dermatitis in posttransplant patients is not established. Previous reports of dupilumab use in posttransplant patients have been in adult patients. In this series, we report three young posttransplant patients treated successfully with dupilumab.
接受实体器官移植的患者患特应性皮炎的风险增加，这可能是由于长期使用钙调神经磷酸酶抑制剂导致免疫反应向Th2偏移所致。度普利尤单抗用于移植后患者治疗特应性皮炎的有效性和安全性尚未确立。既往关于度普利尤单抗用于移植后患者的报道均为成年患者。在本系列报道中，我们报告了3例接受度普利尤单抗治疗成功的年轻移植后患者。
Zotero 插件